Cargando…
Antibody-Drug Conjugates Used in Breast Cancers
The prognosis of breast cancer has radically changed in recent years and continues to improve due to the broad application of effective therapies. New targeting strategies including targeted delivery of cytotoxic drugs via receptor-targeting agents have been developed. We summarize recent publicatio...
Autores principales: | Abbas, Aram J., Ibrahim, Marah F., Saifo, Maher S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257388/ https://www.ncbi.nlm.nih.gov/pubmed/34257655 http://dx.doi.org/10.1155/2021/9927433 |
Ejemplares similares
-
Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021) -
Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review
por: Alali, Mousa, et al.
Publicado: (2023) -
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023) -
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
por: Chen, Yu‐Fei, et al.
Publicado: (2022) -
Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)